Santoni-Rugiu E - Search Results

1

Magnetic resonance imaging with liver-specific contrast agent in primary amyloidosis and intrahepatic cholestasis.

Møller JM, Santoni-Rugiu E, Chabanova E, Løgager V, Hansen AB, Thomsen HS. Møller JM, et al. Acta Radiol. 2007 Mar;48(2):145-9. doi: 10.1080/02841850601128959. Acta Radiol. 2007. PMID: 17354133

2

Molecular prediction of adjuvant cisplatin efficacy in Non-Small Cell Lung Cancer (NSCLC)-validation in two independent cohorts.

Buhl IK, Santoni-Rugiu E, Ravn J, Hansen A, Christensen IJ, Jensen T, Pratt B, Askaa J, Jensen PB, Knudsen S, Sørensen JB. Buhl IK, et al. PLoS One. 2018 Mar 22;13(3):e0194609. doi: 10.1371/journal.pone.0194609. eCollection 2018. PLoS One. 2018. PMID: 29566065 Free PMC article.

3

Progenitor cells in liver regeneration: molecular responses controlling their activation and expansion.

Santoni-Rugiu E, Jelnes P, Thorgeirsson SS, Bisgaard HC. Santoni-Rugiu E, et al. APMIS. 2005 Nov-Dec;113(11-12):876-902. doi: 10.1111/j.1600-0463.2005.apm_386.x. APMIS. 2005. PMID: 16480456 Review.

4

ERCC1 and histopathology in advanced NSCLC patients randomized in a large multicenter phase III trial.

Vilmar AC, Santoni-Rugiu E, Sørensen JB. Vilmar AC, et al. Ann Oncol. 2010 Sep;21(9):1817-1824. doi: 10.1093/annonc/mdq053. Epub 2010 Mar 23. Ann Oncol. 2010. PMID: 20332140 Free article. Clinical Trial.

5

ERCC1, toxicity and quality of life in advanced NSCLC patients randomized in a large multicentre phase III trial.

Vilmar A, Santoni-Rugiu E, Sørensen JB. Vilmar A, et al. Eur J Cancer. 2010 Jun;46(9):1554-62. doi: 10.1016/j.ejca.2010.02.045. Epub 2010 Apr 13. Eur J Cancer. 2010. PMID: 20395129 Clinical Trial.

6

Class III β-tubulin in advanced NSCLC of adenocarcinoma subtype predicts superior outcome in a randomized trial.

Vilmar AC, Santoni-Rugiu E, Sørensen JB. Vilmar AC, et al. Clin Cancer Res. 2011 Aug 1;17(15):5205-14. doi: 10.1158/1078-0432.CCR-11-0658. Epub 2011 Jun 20. Clin Cancer Res. 2011. PMID: 21690572 Clinical Trial.

7

Urokinase plasminogen activator receptor on invasive cancer cells: a prognostic factor in distal gastric adenocarcinoma.

Alpízar-Alpízar W, Christensen IJ, Santoni-Rugiu E, Skarstein A, Ovrebo K, Illemann M, Laerum OD. Alpízar-Alpízar W, et al. Int J Cancer. 2012 Aug 15;131(4):E329-36. doi: 10.1002/ijc.26417. Epub 2011 Oct 20. Int J Cancer. 2012. PMID: 21901747

8

RT-PCR versus immunohistochemistry for correlation and quantification of ERCC1, BRCA1, TUBB3 and RRM1 in NSCLC.

Vilmar A, Garcia-Foncillas J, Huarriz M, Santoni-Rugiu E, Sorensen JB. Vilmar A, et al. Lung Cancer. 2012 Mar;75(3):306-12. doi: 10.1016/j.lungcan.2011.08.016. Epub 2011 Oct 13. Lung Cancer. 2012. PMID: 21996087 Clinical Trial.

9

Low ERCC1 expression in malignant pleural mesotheliomas treated with cisplatin and vinorelbine predicts prolonged progression-free survival.

Zimling ZG, Sørensen JB, Gerds TA, Bech C, Andersen CB, Santoni-Rugiu E. Zimling ZG, et al. J Thorac Oncol. 2012 Jan;7(1):249-56. doi: 10.1097/JTO.0b013e318233d6a9. J Thorac Oncol. 2012. PMID: 22031231 Free article.

10

Are differentially expressed microRNAs useful in the diagnostics of malignant pleural mesothelioma?

Andersen M, Grauslund M, Muhammad-Ali M, Ravn J, Sørensen JB, Andersen CB, Santoni-Rugiu E. Andersen M, et al. APMIS. 2012 Sep;120(9):767-9. doi: 10.1111/j.1600-0463.2012.02891.x. Epub 2012 Mar 5. APMIS. 2012. PMID: 22882267 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

102 results

Search Page

Filters